TPM Research manufactures and markets the Care Continuum Chair—a breakthrough in wheelchair technology delivering dozens of unique benefits for hospital patients, staff, and caregivers.
TPM Research is addressing a long-standing gap in hospital patient care: the transition from bed to chair, lab, bathroom, or vehicle.
For nearly 90 years, the standard solution has been the traditional collapsible wheelchair with its well-known limitations. The Care Continuum Chair changes that with innovative features that deliver superior clinical, aesthetic, and financial outcomes.
Key Differentiators
- Floor-level footrests for safe, easy transfers
- Infinity legrests for optimal positioning
- Patient assist lift for reduced staff strain
- And dozens more advancements designed for real-world hospital needs
The result: better patient experience, safer staff workflows, and measurable cost savings for healthcare facilities.
Proven Leadership
The core executive team—CEO, COO, CFO, and Regulatory Director—previously collaborated to successfully launch, scale, and exit a medical device company (acquired by Stryker in 2018).
To accelerate growth under the new Medline distribution agreement, TPM Research recently added two experienced channel sales directors, including one with direct Medline expertise and established connections.
This combination of serial entrepreneurship and targeted sales talent positions TPM Research for rapid market expansion.
TPM Research has validated its direct sales approach with early wins at major U.S. health systems, including SUNY, Cape Fear Valley, UAB, LCMC, UPMC, Dartmouth Health, and others.
Building on this traction, the company secured a national distribution agreement with Medline, unlocking access to an estimated 306,000-chair addressable market (~$1B opportunity).
TPM Research is also in late-stage discussions with leading healthcare manufacturers for private label and OEM partnerships.
Multi-Channel Strategy
- Medline’s 1,400 sales associates and specialists
- Direct pipeline management
- Targeted industry trade shows
- Customer referrals
- Ongoing OEM/private label negotiations
To date, TPM Research has generated approximately $400,000 in revenue from Care Continuum Chair sales, with a current direct sales pipeline of ~$2 million.
Future growth will be driven primarily through Medline channels, supplemented by direct sales, trade shows, and referrals.
Clinical Validation Driving Demand
- East Jefferson Hospital (LCMC Health)
Exclusive use of the Care Continuum Chair reduced patient falls from 5–10 per month to zero. (Industry average fall cost: ~$45,000 per incident.) A forthcoming white paper will detail this ROI. - Shadyside Hospital (UPMC)
90-day blinded survey showed extraordinarily positive results, including an 88% improvement in patient satisfaction—a metric directly tied to hospital reimbursement.
These studies provide powerful proof points that will accelerate adoption and demonstrate clear financial returns for customers.
Investment Focus
TPM Research is raising capital primarily to fund sales expansion.
Proceeds will support:
- Scaling the sales team and infrastructure
- Maximizing the Medline distribution partnership
- Capitalizing on the current $2M pipeline
- Accelerating penetration of the $1B addressable market
This targeted use of funds positions the company to rapidly grow revenue while leveraging existing traction and clinical validation.
he Care Continuum Chair’s unique technologies are protected by patents licensed long-term from the University of Alabama at Birmingham (UAB), with coverage in the U.S., Canada, much of Europe, and eastern Asia.
Development & Manufacturing Status
- All engineering design and testing completed
- First production run of 250 chairs received (~half sold, remainder in inventory)
- Established production line for improved lead times and margins
- Anticipating volume to support regular monthly production soon
- Perfect FDA on-site inspection in early 2025 confirming full regulatory compliance
TPM Research is de-risked and ready for scaled commercialization.
TPM Research has raised approximately $8 million in Series A and Series B funding to date.
